These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 9604922

  • 1. Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
    Shepherd J, Olsson AG, Sacks FM, Black DM, Orloff DG, Bilheimer DW.
    Am J Cardiol; 1998 Apr 23; 81(8A):88F-94F. PubMed ID: 9604922
    [No Abstract] [Full Text] [Related]

  • 2. What kinds of studies should be required to probe efficacy and safety of drugs in special populations?
    LaRosa JC, Sneider GB, Boyle C.
    Am J Cardiol; 1998 Apr 23; 81(8A):84F-87F. PubMed ID: 9604921
    [No Abstract] [Full Text] [Related]

  • 3. [Lipid distress syndrome in atherosclerosis obliterans].
    Savel'ev VS.
    Vestn Ross Akad Med Nauk; 1999 Apr 23; (9):28-31. PubMed ID: 10523981
    [No Abstract] [Full Text] [Related]

  • 4. Recommendations for Phase IV studies in the development of lipid-lowering drugs.
    Gregg RE.
    Am J Cardiol; 1998 Apr 23; 81(8A):64F-66F. PubMed ID: 9604913
    [No Abstract] [Full Text] [Related]

  • 5. Requirements and methods for documenting diet uniformity and compliance in drug development trials.
    Held J.
    Am J Cardiol; 1998 Apr 23; 81(8A):31F-33F. PubMed ID: 9604903
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Early efficacy and safety studies.
    Sirtori CR.
    Am J Cardiol; 1998 Apr 23; 81(8A):13F-16F. PubMed ID: 9604898
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapy and clinical trials.
    Seed M.
    Curr Opin Lipidol; 1996 Oct 23; 7(5):U168-72. PubMed ID: 8937532
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Primary prevention of ischaemic heart disease with lipid-lowering drugs.
    Lancet; 1988 Feb 13; 1(8581):333-4. PubMed ID: 2893141
    [No Abstract] [Full Text] [Related]

  • 12. Lipid-lowering effects of procetofene.
    Afschrift M, Mets T, Verdonk G.
    Lancet; 1977 Aug 06; 2(8032):311. PubMed ID: 69930
    [No Abstract] [Full Text] [Related]

  • 13. Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies.
    Orloff DG, Blazing MA, O'Connor CM.
    Am Heart J; 1999 Nov 06; 138(5 Pt 1):S406-12. PubMed ID: 10539805
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Effects on the serum lipids of bis (hydroxy-2 ethylthio) 1,10 decane (LL 1558) and clofibrate, based on 91 cases of primary hyperlipoproteinemia].
    Rouffy J.
    Sem Hop Ther; 1973 Jan 06; 49(1):31-6. PubMed ID: 4712022
    [No Abstract] [Full Text] [Related]

  • 17. The future in lipid diseases.
    Lancet; 1977 Oct 15; 2(8042):808. PubMed ID: 71610
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results.
    Moriarty PM.
    Am J Cardiol; 1998 Aug 15; 82(4):505-7. PubMed ID: 9723640
    [Abstract] [Full Text] [Related]

  • 20. Importance of hyperlipidaemia and therapy in renal patients.
    Wanner C.
    Nephrol Dial Transplant; 2000 Aug 15; 15 Suppl 5():92-6. PubMed ID: 11073280
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.